Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial For EOquin(R) In Patients With Non Invasive Bladder Cancer

September 08th, 2007 | Category: Cancer

Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced that it has begun enrolling patients in its second pivotal Phase 3 registrational trial for EOquin, the Company’s drug candidate for non-invasive bladder cancer. The trial design was reviewed under

a previously announced Special Protocol Assessment procedure, which calls for two double-blind, placebo-controlled, randomized clinical trials. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients
  • MicroRNA Expression In Bladder Cancer: A Ratiometric Approach Identifies Invasive Potential
  • Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101
  • Tapestry Initiates Phase 2 Trial Of TPI 287 For The Treatment Of Advanced Pancreatic Cancer
  • Halozyme Therapeutics Completes Enrollment In Chemophase Phase I/IIa Clinical Trial For Superficial Bladder Cancer

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.